logo.png
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
06 mars 2024 09h00 HE | BIOXYTRAN, INC.
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
09 août 2023 16h05 HE | Assembly Biosciences, Inc.
Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024New data for several pipeline programs presented at IHW and EASL 2023Additional development candidate nomination...
AssemblyBio_logo_RGB.png
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
17 juil. 2023 08h00 HE | Assembly Biosciences, Inc.
-- First presentation of preclinical data describing the activity, pharmacokinetics and safety profile of ABI-5366, supporting planned clinical entry in 1H 2024 -- SOUTH SAN FRANCISCO, Calif.,...
TIP_link_300x300.jpg
Male Condoms Market to Reach $13.97Bn by 2028 at 8% CAGR with Non-Latex Segment Driving Growth During 2022–2028 | The Insight Partners
04 juil. 2023 08h21 HE | The Insight Partners
Pune, India, July 04, 2023 (GLOBE NEWSWIRE) -- According to Recently Published Report by The Insight Partners, “Male Condoms Market Size Report, Forecast to 2028 - COVID-19 Impact and Global...
AssemblyBio_logo_RGB.png
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
07 juin 2023 08h00 HE | Assembly Biosciences, Inc.
-- International Herpesvirus Workshop will feature oral and poster presentations of preclinical data from ABI-5366, Assembly Bio’s first herpesvirus development candidate -- -- Five posters accepted...
TIP_link_300x300.jpg
Anti-Viral Therapies Market Growth ($82.92 Billion by 2028) Driven by Branded Drugs Segment during (2022-2028) – Global Report by The Insight Partners
09 mars 2023 08h46 HE | The Insight Partners
New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global...
AssemblyBio_logo_RGB.png
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
15 févr. 2023 08h00 HE | Assembly Biosciences, Inc.
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN...
researchdrivelogo.jpg
Global Antiviral Therapy Market Expected to Generate a Revenue of $79.8 Million by 2026, Growing at a CAGR of 6.7% From 2019-2026 COVID-19 Impact - Exclusive Report by Research Dive
14 sept. 2021 09h01 HE | Research Dive
New York, USA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global antiviral therapy market is expected to generate a revenue of $79.8 million by 2026,...
HerpaGreens Reviews
HerpaGreens Review - Negative Side Effects or Real Benefits?
16 avr. 2021 02h33 HE | Marketing By Kevin
Chicago, IL, April 16, 2021 (GLOBE NEWSWIRE) -- Have you recently been diagnosed with herpes? Is that all that’s been echoing in your head lately? If yes, this isn’t surprising to us, considering...
researchdrivelogo.jpg
Global Antiviral Therapies Market Expected to Surpass to $66,016.5 Million and Exhibit a CAGR of 3.1% from 2020 to 2027 - Exclusive Report [Pages - 208] by Research Dive
12 avr. 2021 09h15 HE | Research Dive
New York, USA , April 12, 2021 (GLOBE NEWSWIRE) -- Research Dive in its latest published report estimates that the global antiviral therapies market will generate $66,016.5 million and exhibit...